CHICAGO--(BUSINESS WIRE)-- Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to oncology guidelines each year make it difficult for the updates to be rapidly... (continue reading...)
TORONTO--(BUSINESS WIRE)-- Postmedia Network Inc., a wholly owned subsidiary of Postmedia Network Canada Corp. (“Postmedia” or “the Company”) today announced that it has closed its previously announced sale of the Winnipeg Sun, The Graphic Leader, Kenora Miner & News and the Winnipeg Press Commercial Print division to the Klein Group Ltd. (the “Klein Group”).
About Postmedia Network Canada Corp.
Postmedia Network Canada Corp. (TSX:PNC.A, PNC.B) is... (continue reading...)
Ankyra Therapeutics will provide an update on the status of the ANK-101 Phase 1 ANCHOR clinical trial at ASCO 2024 and has received approval by FDA and Health Canada to amend the Phase I study to include patients with solid tumors in visceral organs
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced today that it is... (continue reading...)
NEW YORK--(BUSINESS WIRE)-- Since 2019, Sally Hansen® has committed to partnering with GLAAD to support Pride and the organization’s mission to accelerate acceptance for the LGBTQ+ community. In the spirit of Pride 2024, this year’s NEW Sally Hansen® x Pride Limited-Edition Collection includes 11 metallic shades of the Progress Pride flag and 3 Salon Effects® Perfect Manicure designs modeled after the Trans, Bi, and Progress Pride flag!
The new Sally Hansen... (continue reading...)
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study
Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years
TRUST-I is one of two registrational Phase 2 studies evaluating taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC
NEW YORK--(BUSINESS... (continue reading...)
More Business Wire
View Older Stories-
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
-
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
-
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
-
Clariane: Information on the Availability of an Amendment to the 2023 Universal Registration Document
-
AnalytixInsight Reports 2023 Financial Results and Provides MCTO Status Update
-
The Chemours Company Temporarily Pauses Titanium Dioxide Production at Altamira, Mexico Site Amid Severe Regional Drought
-
Generation Mining Files Final Base Shelf Prospectus and Updates Shareholders
-
Tikehau Capital: Disclosure of shares repurchases from 24 May 2024 to 30 May 2024
-
Government Regulation Creates Blue Oceans
-
Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing
-
Leading Independent Proxy Advisory Firm Institutional Shareholder Services Joins Glass Lewis in Recommending Votes “FOR” ALL Nine WisdomTree Board Nominees
-
BRW Announces Notification of Sources of Distributions
-
SABA Announces Notification of Sources of Distributions
-
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Che
-
FCPT Announces Acquisition of a Mavis Tire Property for $2.4 Million
-
University of Phoenix and Executive Networks Study on Workplace Well-Being Highlights Challenges of Current Approaches in Addressing Mental Health
-
Capstone Copper Announces Retirement of Robert Gallagher from the Board of Directors
-
Drive Shack Inc. Releases Fourth Quarter and Full-Year 2023 Financial Results
-
Medical Properties Trust Publishes Its Third Annual Corporate Responsibility Report
-
FCPT Announces Acquisition of a National Veterinary Associates Property for $2.0 Million
-
Fonon's Additive Manufacturing Technology To Transform Construction Industry
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Ventas to Present at Nareit’s REITweek 2024 Investor Conference
-
Korn Ferry Recognized for Seventh Consecutive Year as a Leader in Everest Group’s Recruitment Process Outsourcing (RPO) Services PEAK Matrix® Assessment 2024
-
Boston Omaha Corporation Announces Date for 2024 Annual Meeting of Stockholders
-
Darwin’s Natural Pet Products Continues Ongoing Partnership with PAWS for Annual PAWS Walk
-
Ault Disruptive Technologies Responds to Unusual Market Activity
-
Hope Biosciences Research Foundation Announces Topline Results of Cell Therapy Clinical Trial in Long COVID
-
State Street Corporation (NYSE: STT) Announces Date for Release of Second-Quarter 2024 Financial Results and Conference Call Webcast
-
MedX Health Corp. announces proposed extension of Non-brokered Private Placement offering
-
SITE Centers Declares Second Quarter 2024 Class A Preferred Share Dividend
-
Equity Residential to Participate in Nareit REITweek Conference
-
UBS Announces Assumption of Three Outstanding Credit Suisse ETNs; Rebranding as “ETRACS”
-
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
-
PulteGroup, Inc. Announces Pricing for Tender Offers for Senior Notes
-
Westlake Chemical Partners Provides Tax Reporting Information
-
Camden Property Trust Announces Participation in Nareit’s REITweek 2024 Investor Conference and Provides Second Quarter 2024 Operating Update
-
Pacific Coast Oil Trust Announces There Will Be No May Cash Distribution
-
AvalonBay Communities, Inc. Announces Participation in Nareit’s REITweek Conference, Provides Second Quarter 2024 Operating Update, and Publishes Updated Investor Presentation
-
PGIM Closed End Funds Declare Distributions for June, July and August 2024
-
Emerald to Participate in Maxim Group TMT Conference
-
Bradley E. Cooper Appointed to Hamilton Board of Directors
-
Eaton Expands Reach into European Data Center Market by Making Strategic Investment in NordicEPOD
-
First Trust Advisors L.P. Announces Distribution for Exchange-Traded Funds
-
Asana to Present at Upcoming Investor Events